Targeting HMGB2 may disrupt these critical pathways involved in the metabolic reprogramming of cancer cells, thereby inhibiting tumor growth and progression, offering a promising avenue for improving patient outcomes. This evidence concerns the gene HMGB2 and neoplasm.